1-cyclohexyl-3-methylimidazolidin-2,4-dione | 63760-93-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 1-cyclohexyl-3-methylimidazolidin-2,4-dione
• 英文别名: 1-cyclohexyl-3-methylhydantoin；1-cyclohexyl-3-methyl-imidazolidine-2,4-dione；Imidazolidine-2,4-dione, 1-cyclohexyl-3-methyl-；1-cyclohexyl-3-methylimidazolidine-2,4-dione
• CAS: 63760-93-0
• 化学式: C₁₀H₁₆N₂O₂
• mdl: MFCD03923804
• 分子量: 196.249
• InChiKey: KKRHFSGBFULTCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-环己基-3-甲基脲 、 邻甲酚 、 马来酸二甲酯 、 3-Cyclohexyl-1-methyl-imidazolidine-2,4-dione 、 1-cyclohexyl-3-methylimidazolidin-2,4-dione 在 甲醇 作用下， 185.0~200.0 ℃ 、1.42 kPa 条件下， 反应 2.0h， 以a main fraction boiling at 180°-185° C/0.08 Torr could be isolated的产率得到1-Methyl[cyclohexyl]-3-cyclohexyl[methyl]-5-(methoxy-carbonyl-methylene)-hydantoin
  参考文献：
  名称：

  Preparation of hydantoins by reacting esters of

  摘要：

  一种制备带有羧酸酯基团的（硫）氢嘧啶衍生物的过程，其中可以被取代的1,2-乙烯二羧酸酯与（硫）脲化合物在单步反应中反应。

  公开号：

  US04089860A1
• 作为产物：
  描述：

  1-环己基-3-甲基脲 在 盐酸 、 碳酸氢钠 作用下， 以 甲醇 、 水 为溶剂， 反应 4.0h， 生成 1-cyclohexyl-3-methylimidazolidin-2,4-dione
  参考文献：
  名称：

  3,3'-双（6,8-二烷基-2,4-二氧杂-6,8-二氮杂双环[3.3.0] octan-7-ones的首个代表化合物的合成

  摘要：

  3,3'-bi（2,4-dioxa-6,8-diazabicyclo [3.3.0] octan-7-ones）的第一个代表是通过乙二醛以2,2'-bi的形式合成的（4，5-二羟基-1，3-二氧杂戊环）与N，N′-二烷基脲。X射线分析支持了它们的结构。1,3-二烷基咪唑烷-2,4-二酮（乙内酰脲）已被分离为副产物，其形成机理已通过实验证实。

  DOI：

  10.1002/jhet.5570430523

文献信息

• Synthesis of new chiral mono-, di-, tri-, and tetraalkylglycolurils
  作者：A. N. Kravchenko、A. S. Sigachev、E. Yu. Maksareva、G. A. Gazieva、N. S. Trunova、B. V. Lozhkin、T. S. Pivina、M. M. Il’in、K. A. Lyssenko、Yu. V. Nelyubina、V. A. Davankov、O. V. Lebedev、N. N. Makhova、V. A. Tartakovsky

  DOI：10.1007/s11172-005-0307-3

  日期：2005.3

  Two general procedures were developed for the synthesis of chiral N-mono-, N, N′-di-, N, N′ N″-tri-, and N, N′, N″, N′″-tetraalkylglycolurils based on the reactions of 4,5-dihydroxy-imidazolidin-2-ones or glyoxal with one or two moles of alkylureas, respectively, by acid catalysis. The reactions of N-monoalkyl- and N, N′-dialkylureas with glyoxal proceed regioselectively. The mechanism of these reactions was suggested and partly confirmed by quantum-chemical calculations and experimental data. The enantiomeric separation of some chiral glycolurils by chiral-phase HPLC was carried out for the first time.

  在 4,5-二羟基咪唑烷-2-酮或乙二醛分别与一或两摩尔烷基脲在酸催化下发生反应的基础上，开发了合成手性 N-单烷基、N, N′-二烷基、N, N′-三烷基和 N, N′,N″,N′″-四烷基乙二醛的两种一般程序。N-单烷基和 N，N′-二烷基脲与乙二醛的反应具有区域选择性。量子化学计算和实验数据提出并部分证实了这些反应的机理。首次利用手性相高效液相色谱法分离了一些手性羟基乙醛的对映体。
• Pharmaceutical composition containing a hydantoin derivative and use of said derivative
  申请人：NIPPON ZOKI PHARMACEUTICAL CO., LTD.

  公开号：EP0780125A2

  公开（公告）日：1997-06-25

  The present invention is directed to a pharmaceutical composition comprising a hydantoin derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof wherein each of R1 and R2, which may be the same or different, represents hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represents hydrogen, hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group, and a pharmaceutically acceptable carrier or diluent. The above mentioned hydantoin derivative has an action of eliminating the active oxygen and the free radicals. Accordingly, it is useful for preparing a pharmaceutical agent for treating a variety of diseases in which active oxygen and free radicals are participated such as myocardial infarction, reperfusion disturbance, autoimmune diseases, fibrosis, pulmonary diseases, dermatological diseases, arthropathy, side effects of anticancer agents, radiation diseases, septic shock, inflammatory diseases and cataract.

  本发明涉及一种药物组合物，该药物组合物包含下式（I）所代表的 hydantoin 衍生物或其药学上可接受的盐 其中R1和R2（可以相同或不同）各自代表氢、烷基或环烷基；X和Y（可以相同或不同）各自代表氢、羟基、烷基或烷氧基，或X和Y共同代表氧代基团，以及药学上可接受的载体或稀释剂。 上述海因衍生物具有消除活性氧和自由基的作用。因此，它可用于制备治疗各种参与活性氧和自由基的疾病的药剂，如心肌梗塞、再灌注障碍、自身免疫性疾病、纤维化、肺部疾病、皮肤病、关节病、抗癌剂副作用、放射病、脓毒性休克、炎症性疾病和白内障。
• Therapeutic agent for intractable vasculitis
  申请人：NIPPON ZOKI PHARMACEUTICAL CO., LTD.

  公开号：EP1018339A1

  公开（公告）日：2000-07-12

  The invention provides a therapeutic agent for intractable vasculitis containing a hydantoin derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof as an effective ingredient: wherein R1 and R2, which may be the same or different, represent hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represent hydrogen, a hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group. These compounds significantly suppress the generation of arthritis and arteritis (cutaneous ulcer and auricular infarcted necrosis) which were naturally developed in model animals (MRL/lpr), and further significantly elongat the survival rate of MRL/lpr mice. Consequently, the compound of the invention having low toxicity and less side effects is very useful as a highly safe therapeutic agent for intractable vasculitis such as malignant rheumatoid arthritis.

  本发明提供了一种治疗难治性脉管炎的药物，其有效成分含有由式（I）代表的海因衍生物或其药学上可接受的盐： 其中R1和R2可以相同或不同，分别代表氢、烷基或环烷基；X和Y可以相同或不同，分别代表氢、羟基、烷基或烷氧基，或X和Y共同代表氧代基团。 这些化合物能明显抑制模型动物（MRL/lpr）自然产生的关节炎和动脉炎（皮肤溃疡和耳廓梗塞坏死），并进一步明显延长 MRL/lpr 小鼠的存活率。因此，本发明的化合物毒性低、副作用小，是一种非常有用的治疗顽固性血管炎（如恶性类风湿性关节炎）的高安全性药物。
• Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia
  申请人：NIPPON ZOKI PHARMACEUTICAL CO., LTD.

  公开号：EP1243261A1

  公开（公告）日：2002-09-25

  Disclosed is the use of a hydantoin derivative of the formula (I) wherein R1 and R2 each independently is H, alkyl or cycloalkyl; and X and Y each independently is H, OH, alkyl or alkoxy, or X and Y together form an oxo group, or a pharmaceutically acceptable salt, hydrate or complex thereof, for the manufacture of a medicament effective in the treatment of hypoalbuminaemia.

  公开了一种式（I）的海因衍生物的用途 其中 R1 和 R2 各自独立地为 H、烷基或环烷基；X 和 Y 各自独立地为 H、OH、烷基或烷氧基，或 X 和 Y 共同形成一个氧代基团，或其药学上可接受的盐、水合物或络合物，用于制造对治疗低白蛋白血症有效的药物。
• CARCINOGENESIS INHIBITOR
  申请人：National Cancer Center

  公开号：EP3639821A1

  公开（公告）日：2020-04-22

  An object of the present invention is to provide a carcinogenesis inhibitor having no side effect and having an excellent effect by oral administration. A carcinogenesis inhibitor of the present invention containing a hydantoin derivative or a pharmaceutically acceptable salt thereof as an active ingredient shows an inhibiting action for polyp formation and for cell proliferation, and has no side effect and highly safe whereby it is very highly useful as a pharmaceutical agent and a food such as supplement which prevent the occurrence and progress of cancer, inhibits the recurrence and metastasis of cancer and further achieves the therapeutic effect.

  本发明的目的是提供一种口服无副作用且效果极佳的致癌物抑制剂。 本发明的一种致癌抑制剂含有一种海因衍生物或其药学上可接受的盐作为有效成分，对息肉的形成和细胞增殖有抑制作用，且无副作用，安全性高，因此作为药物制剂和食品（如保健品）非常有用，可以防止癌症的发生和发展，抑制癌症的复发和转移，并进一步达到治疗效果。